# **Bone Scan Whole Body**

#### Indications

> To assess osseous metastatic disease and staging, primary benign and malignant osseous lesions, arthritides, unexplained bone pain, accidental and nonaccidental trauma, further evaluation of osseous abnormalities incidentally found on other imaging exams, heterotopic ossification, Paget disease, fibrous dysplasia, hypertrophic osteoarthropathy and bone manifestations of sickle cell disease.

## • Radiopharmaceutical:

> 25.0 mCi Tc-99m MDP (methyl diphosphonate) administered IV

# • Patient Preparation/Aftercare:

- > No specific preparation prior to radionuclide administration.
- > Hydrate the patient after radionuclide administration. Instruct the patient to hydrate for a day following the exam.
- ➤ Have the patient empty his/her bladder immediately prior to imaging. Instruct the patient to void frequently for a day following the exam.

## • Conflicting Examinations/Medications:

- No Nuclear Medicine exams within the previous 24 hrs.
- ➤ No barium GI exams within the previous 48 hrs.

## • Pregnancy/Lactation:

- Pregnancy testing is only needed in potentially pregnant patients who state they could be pregnant. See Pregnant, Potentially Pregnant and Lactating Patients policy for specifics.
- > Breast feeding mothers should discard breast milk for 4-24 hrs following Tc-99m MDP administration.

# • Imaging Technique:

- ➤ Collimator LEHR or LEAP
- ➤ Photopeak 140 keV 20% window for Tc-99m
- ➤ Image Preset Counts
  - o Whole Body Images adjust scanning speed (cm/min) to obtain at least 1.5 million counts per image
  - Static Images
    - ✓ Torso/Pelvis 750k counts/image or 5 mins/image
    - ✓ Skull/Extremities 500k counts/image or 5 mins/image
- Matrix Size 256 x 1024 (whole body), 256 x 256 (static)
- > Patient Positioning supine

#### Images/Views:

- > Begin imaging 3-4 hrs after radionuclide administration.
- > Obtain anterior and posterior whole body images.
- > Obtain anterior and posterior static images of the torso and pelvis.
- Add oblique and/or lateral static images of any focal findings at the discretion of the Nuclear Medicine Technologist.
- > Check with the Radiologist before discharging the patient to see if any additional imaging is needed.
- Use XR Addl Films w/ Nuclear Med Study for any radiographs requested by the Radiologist. Sign the order for the radiographs back to whomever ordered the bone scan.

#### • Notes:

- > Uptake on bone scans reflects osteoblastic activity. Bone scans have limited sensitivity in the assessment of osteolytic lesions.
- An increase in the uptake intensity or the number of abnormalities may indicate disease progression or flare response (due to increased osteoblastic activity during repair).
- Increased uptake associated with healed fractures can persist for up to 2 years (even longer in presence of internal fixation hardware).
- Diffuse increased soft tissue uptake can be caused by renal failure, dehydration, a shortened interval between injection and imaging, trauma or the use of the wrong energy window for image acquisition.

- Focal increased soft tissue uptake can be caused by localized infection or inflammation, trauma, infarction and soft tissue metastasis (particularly from mucinous primary lesions).
- Diffuse decreased soft tissue uptake can reflect a superscan (diffusely increased uptake in bone) or result from a prolonged interval between injection and imaging (focal or diffuse uptake).
- Medications that interfere with uptake include aluminum-containing compounds, corticosteroids, iron, methotrexate, nifedipine (Procardia), hematopoietic growth factors (Epogen, Neupogen, Neulasta), androgen deprivation therapy, estrogens, bisphosphonates, medications that interfere with osteoblastic function, nephrotoxic chemotherapy and amino caproic acid.